Chembio Diagnostics Inc (NASDAQ:CEMI) CFO Neil A. Goldman purchased 14,815 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $6.75 per share, with a total value of $100,001.25. Following the completion of the acquisition, the chief financial officer now directly owns 14,815 shares of the company’s stock, valued at $100,001.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Chembio Diagnostics Inc (NASDAQ CEMI) traded up $0.20 during trading on Tuesday, hitting $7.40. The stock had a trading volume of 144,400 shares, compared to its average volume of 30,288. Chembio Diagnostics Inc has a 52-week low of $5.05 and a 52-week high of $9.20. The company has a quick ratio of 2.19, a current ratio of 3.54 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $88.70, a price-to-earnings ratio of -12.98 and a beta of 1.14.
Several institutional investors have recently bought and sold shares of the company. Benchmark Capital Advisors boosted its holdings in shares of Chembio Diagnostics by 174.2% in the third quarter. Benchmark Capital Advisors now owns 32,900 shares of the company’s stock worth $204,000 after acquiring an additional 20,900 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Chembio Diagnostics in the second quarter worth $151,000. Wells Fargo & Company MN boosted its holdings in shares of Chembio Diagnostics by 55.4% in the second quarter. Wells Fargo & Company MN now owns 74,186 shares of the company’s stock worth $449,000 after acquiring an additional 26,436 shares during the period. Finally, Royce & Associates LP boosted its holdings in shares of Chembio Diagnostics by 367.6% in the fourth quarter. Royce & Associates LP now owns 102,400 shares of the company’s stock worth $840,000 after acquiring an additional 80,500 shares during the period. 34.00% of the stock is owned by hedge funds and other institutional investors.
About Chembio Diagnostics
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.